Greenwich LifeSciences, Inc. carries no debt; cash flow comfortably covers obligations.

Greenwich LifeSciences, Inc.'s free cash flow has decreased 36.43% from $-7.27M last year to $-9.91M, signaling decreasing performance

Greenwich LifeSciences, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Greenwich LifeSciences, Inc. has insufficient data to evaluate this check.

Greenwich LifeSciences, Inc. has negative EBITDA, making leverage ratio unreliable

Greenwich LifeSciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Greenwich LifeSciences, Inc. has insufficient data to evaluate this check.

Greenwich LifeSciences, Inc.'s short-term assets of $6.18M exceed its short-term liabilities of $5.82M

Greenwich LifeSciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Greenwich LifeSciences, Inc.'s return on equity of -941.06%, is lower than 15.00%, indicating bad performance

Greenwich LifeSciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Greenwich LifeSciences, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Greenwich LifeSciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Greenwich LifeSciences, Inc. has negative free cash flow, indicating cash burn

Greenwich LifeSciences, Inc.'s yearly earnings has decreased 11.16% since last year from $-17.41M to $-19.36M, signaling decreasing performance

Greenwich LifeSciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -415.38% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Greenwich LifeSciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Greenwich LifeSciences, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Greenwich LifeSciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Greenwich LifeSciences, Inc. has insufficient data to evaluate this check.

Greenwich LifeSciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Greenwich LifeSciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Greenwich LifeSciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Greenwich LifeSciences, Inc. has insufficient data to evaluate this check.

Greenwich LifeSciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Greenwich LifeSciences, Inc. has a price-to-book ratio of 54.72x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Greenwich LifeSciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue